HUE027077T2 - Antitestes terapeutika az emésztõrendszerben jelentkezõ helyi aktivitással - Google Patents

Antitestes terapeutika az emésztõrendszerben jelentkezõ helyi aktivitással Download PDF

Info

Publication number
HUE027077T2
HUE027077T2 HUE10824210A HUE10824210A HUE027077T2 HU E027077 T2 HUE027077 T2 HU E027077T2 HU E10824210 A HUE10824210 A HU E10824210A HU E10824210 A HUE10824210 A HU E10824210A HU E027077 T2 HUE027077 T2 HU E027077T2
Authority
HU
Hungary
Prior art keywords
antibody
tnf
serum
bovine
antibodies
Prior art date
Application number
HUE10824210A
Other languages
English (en)
Inventor
Barbara S Fox
Douglas C Stafford
Original Assignee
Avaxia Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avaxia Biologics Inc filed Critical Avaxia Biologics Inc
Publication of HUE027077T2 publication Critical patent/HUE027077T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Claims (4)

  1. ANÜTESTESTEEAFEO ilKA AZ EMÍSO'ÓKE«ZE&BEŐl JMNTKEZŐ HELYI AKTIVITÁSSAL SZABADAIÄ10ΕΉ ΥΕΟΜΤΌΚ ; í. :%y asíHTblF pölüdonáíts antitest, amely lejből «agy fcolosaíransbó! származik, «s a gyulladásos Mibetegség kezelésére szolgáié módszerben való; használatra szolgál egy páciensben, aboi m te#TblE polMonálls antitestnek » pMteáS «îbÔS2#fe8dszerébe iőrlÉ# MMâsa «iàîs « páciens szérmnábanlevő anti-TMF polikkmáJís antitest esáPSSzfet|ő ILlSÁ-val mérve kevesebb, mint 500 ng/ml.
  2. 2. Az L ippypast szerint alkalmazandó and-TMF políklonális antitest, ahol az ann-TNF sttifckt: J vagy több dózisának adagtÄäbsns csökkenti az ami-ÎNF antitest iMásósságáí é hónap álátl.
  3. 3. Az 1, igénypont szerint használandó anti-TNF péiilíipBáSs antitest abol aki ántLTMÉ póilklöoáÉs MÍiÓSS beadása után a beteg: szérumába« az anil-THE ptdifclónálls antitest kimutatható esiksszítstj© kevesebb, íinírü 10 ngknl
  4. 4. Az I, igénypont szeráÉ használandó and-Tb!F poliklhaâis antitest, ahol az. anti-TMF poíiklfönálls antitestet orális vagy rekíális adagolásra tormulázták. S. Az 1-4, igénypfntók bÉ-melyike szerint használandó aaíLTNF antitest, ahol az aníi-TblT peliklönális antitest szarvasmarhábéi származik.
HUE10824210A 2009-10-15 2010-10-15 Antitestes terapeutika az emésztõrendszerben jelentkezõ helyi aktivitással HUE027077T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25199609P 2009-10-15 2009-10-15

Publications (1)

Publication Number Publication Date
HUE027077T2 true HUE027077T2 (hu) 2016-08-29

Family

ID=43876600

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE10824210A HUE027077T2 (hu) 2009-10-15 2010-10-15 Antitestes terapeutika az emésztõrendszerben jelentkezõ helyi aktivitással

Country Status (14)

Country Link
US (3) US20120258118A1 (hu)
EP (2) EP2992900A1 (hu)
JP (1) JP2013508300A (hu)
KR (1) KR20120098664A (hu)
CN (1) CN102596248A (hu)
AU (1) AU2010306563B2 (hu)
CA (1) CA2777823A1 (hu)
ES (1) ES2547872T3 (hu)
HK (1) HK1173973A1 (hu)
HU (1) HUE027077T2 (hu)
NZ (1) NZ599315A (hu)
PL (1) PL2488202T3 (hu)
PT (1) PT2488202E (hu)
WO (1) WO2011047328A1 (hu)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009046168A1 (en) 2007-10-02 2009-04-09 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
WO2012058769A1 (en) * 2010-11-03 2012-05-10 Mcmaster University Method of treating mucosal inflammation
EP2739650A4 (en) * 2011-08-01 2015-04-01 Avaxia Biologics Inc SPECIFIC BOVINE POLYCLONAL ANTIBODY OF HUMAN TNF
US9580501B2 (en) * 2011-12-16 2017-02-28 Synthon Biopharmaceuticals B.V. Anti-TNF alpha monoclonal secretory IgA antibodies and methods for treating inflammatory diseases
EP3092253B1 (en) 2014-01-10 2021-03-17 AnaptysBio, Inc. Antibodies directed against interleukin-33 (il-33)
FR3022462B1 (fr) * 2014-06-18 2018-04-27 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Composition orale d'anticorps anti-tnfalpha
GB201701404D0 (en) * 2017-01-27 2017-03-15 Micropharm Ltd Therapies for treating inflammatory disorders
EP3409688A1 (en) 2017-05-31 2018-12-05 Tillotts Pharma Ag Topical treatment of inflammatory bowel disease using anti-tnf-alpha antibodies and fragments thereof
EP3553155A1 (en) 2018-03-12 2019-10-16 INDIAN OIL CORPORATION Ltd. Nano perovskite materials as combustion improver for liquid and gaseous fuels
GB201812261D0 (en) * 2018-07-27 2018-09-12 Micropharm Ltd Therapies for treating oral mucositis
CN110672860B (zh) * 2019-11-04 2023-07-14 中国科学院近代物理研究所 五种细胞因子组合作为电离辐射损伤生物标志物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4330338A (en) 1978-10-02 1982-05-18 Purdue Research Foundation Pharmaceutical coating composition, and preparation and dosages so coated
US4518433A (en) 1982-11-08 1985-05-21 Fmc Corporation Enteric coating for pharmaceutical dosage forms
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5126130A (en) 1986-11-24 1992-06-30 The Childrens Hospital Incorporated Monoclonal antibodies reactive with specific antigenic sites on human cytomegalovirus glycoprotein a
AU667533B2 (en) * 1992-03-26 1996-03-28 Microcarb, Inc. Monospecific polyclonal antibodies to shiga-like toxins
US20030186882A1 (en) * 2001-07-31 2003-10-02 Podolsky Daniel K. Methods and compositions for treating and preventing distal bowel lesions
US6395273B1 (en) * 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease
JP4589914B2 (ja) 2003-01-07 2010-12-01 シムフォゲン・アクティーゼルスカブ 組換え型ポリクローナルタンパク質の製造方法
US20040185047A1 (en) * 2003-03-21 2004-09-23 Jill Giles-Komar Anti- TNF antibodies, compositions, methods and uses
EP1982999A1 (en) * 2007-04-16 2008-10-22 Friesland Brands B.V. Milk derived antigen specific antibodies, methods of preparation and uses thereof
AU2008239935A1 (en) * 2007-04-16 2008-10-23 Friesland Brands B.V. Milk derived antigen specific antibodies, methods of preparation and uses thereof
WO2009020748A2 (en) * 2007-07-16 2009-02-12 Avaxia Biologics, Inc. Antibody therapy for modulating function of intestinal receptors
WO2009046168A1 (en) 2007-10-02 2009-04-09 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract

Also Published As

Publication number Publication date
US20170008957A1 (en) 2017-01-12
US20120258118A1 (en) 2012-10-11
EP2488202B1 (en) 2015-07-08
AU2010306563B2 (en) 2013-11-28
PT2488202E (pt) 2015-10-19
AU2010306563A1 (en) 2012-05-03
JP2013508300A (ja) 2013-03-07
EP2488202A4 (en) 2013-01-23
US20140010822A1 (en) 2014-01-09
CA2777823A1 (en) 2011-04-21
NZ599315A (en) 2014-05-30
HK1173973A1 (en) 2013-05-31
WO2011047328A1 (en) 2011-04-21
KR20120098664A (ko) 2012-09-05
PL2488202T3 (pl) 2015-12-31
EP2488202A1 (en) 2012-08-22
ES2547872T3 (es) 2015-10-09
CN102596248A (zh) 2012-07-18
EP2992900A1 (en) 2016-03-09

Similar Documents

Publication Publication Date Title
EP2488202B1 (en) Antibody therapeutics with local activity in the digestive tract
CA2734139C (en) Antibody therapy for use in the digestive tract
US9079955B2 (en) Compositions comprising TNF-specific antibodies for oral delivery and methods of use thereof to treat inflammatory bowel disease
JP2016516686A (ja) 抗ｉｌ２３抗体を使用してクローン病を治療するための方法
WO2016086147A1 (en) Vedolizumab for the treatment of fistulizing crohn's disease
US20220008533A1 (en) Composition and methods of treating inflammatory and autoimmune diseases
WO2007056301A2 (en) Antibody therapy for treatment of diseases associated with gluten intolerance
Griffiths et al. Inflammatory bowel disease and targeted oral anti-TNFα therapy
US20230227555A1 (en) Cd-3 antibodies for the treatment of coronavirus
JP2022544992A (ja) クローン病を治療するためのブラジクマブの使用
US8268971B2 (en) Antibody therapy for modulating function of intestinal receptors and methods of treating diabetes and obesity
AU2013245509A1 (en) Antibody therapeutics with local activity in the digestive tract
TW202126330A (zh) 全身性硬化症治療用醫藥組合物
JPWO2020215019A5 (hu)
JP2001081049A (ja) 胃炎・胃又は十二指腸潰瘍治療・予防剤